~~<i id='8DDED5339A'><strike id='8DDED5339A'><tt id='8DDED5339A'><pre id='8DDED5339A'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

author：hotspot 2025-08-19 06:17:30 - browse：6

The Food and Drug Administration on Thursday approved a gene therapy to treat people with hemophilia A, an inherited and rare bleeding disorder.

The treatment, called Roctavian, is made by BioMarin Pharmaceutical. It was first approved in Europe in August 2022.

Roctavian is a one-time therapy that, in clinical trials, dramatically reduced bleeding episodes and helped patients live without the blood transfusions used to treat the disease. The FDA first rejected Roctavian in 2020, asking BioMarin to amass more data on its safety and long-term durability, and then delayed its decision again to account for additional evidence.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： The (many) problems with a new study criticizing cancer screening

focus

hotspot

AdobeArecentstudypromptedCNNtoreport,“Mostcancerscreeningsdon’tultimatelygivesomeoneextratimebeyondt

WSS

Listen: Biogen's potential pivot, & Illumina's next chapter

Google's generative AI to analyze medical images — and talk to docs

Advances in CAR

Covid hospitalizations on the rise, Humana says

St. Louis police protesters begin picking up checks in $4.9 million settlement

Crinetics acromegaly drug succeeds in late

hotspot

hotspot

focus

Virginia high school admissions case could be legal follow

Russia promises retaliation after Ukrainian drones hit a Russian tanker in 2nd sea attack in a day

Affirmative action in medical school literally saved lives

Failure, not just success, should guide future doctors

Heart attack and stroke risk calculators need revising

Failure, not just success, should guide future doctors

23andMe had bad news about my health. I wish a person had delivered it

Advances in CAR

Cancer drug shortages should be causing more outrage

Pennsylvania man bitten on the head by bear during attack in his garage

focus

Illumina names Agilent executive as new CEO

Slovenia has suffered its worst

House transparency, PBM reform bill gains bipartisan support

How to fix cancer clinical trials' diversity problem

Doctors are clamoring for more clarity on Paxlovid prescribing

St. Louis police protesters begin picking up checks in $4.9 million settlement

focus

focus

hotspot

hotspot